A novel inhibitor of plasminogen activator inhibitor-1 production, T-686: Direct effects on the fibrinolytic system

Fibrinolysis and Proteolysis

Volumn 11, Issue 1, 1997, Pages 45-50

  Ohtani, A ^a   Murakami, J ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYLIDENE 4 (3,4,5 TRIMETHOXYBENZYLIDENE)SUCCINIMIDE; LIPOPOLYSACCHARIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031001701     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80008-2     Document Type: Article

References (33)

1. Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor-1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 203-276.
2. Schneider J, Loskutoff D J. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991; 1: 99-102.
3. Loskutoff D J, Sawdey M, MimuroJ. Type l plasminogen activator inhibitor. In: Coller B, ed. Progress in Haemostasis and Thrombosis. WB Saunders, Philadelphia, 1989; 9: 87-115.
4. Masuda T, Yasue H, Ogawa H et al. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992; 124: 314-319.
5. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart] 1988; 59: 535-541.
6. Musumi I, Ogawa H, Masuda T, Sakamoto T, Okumura K, Yasue H. Increased plasma plasminogen activator inhibitor activity after coronary spasm. IntJ Cardiol 1993; 41: 21-29.
7. Nilsson I M, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br MedJ 1985; 290: 1453-1456.
8. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1987; 105: 265-270.
9. Juhan-Vague I, Valadier J, Alessi M C et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
10. Erickson L A, Fici G J, Lund J E, Boyle T P, Polites H G, Marotti K R. Development venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76.
11. Carmeliet P, Stassen J M, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice: II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
12. Ohtani A, Takagi T, Hirano A, Murakami J, Sasaki Y. Inhibitory effect of a new butadiene derivative on the production of plasminogen activator inhibitor-1 in cultured bovine endothelial cells. J Biochem 1996; 120: 1203-1208.
13. Vinogradsky B, Bell S P, Okada H, Guala A S, Thornton D, Fujii S. A new butadiene derivative, T-686, modulates development of atherosclerosis in vivo in rabbits. J Am Coll Cardiol 1996; 27(Supplement A): 64A.
14. Sawa H, Sobel B E, Fujii S. Inhibition of type 1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994; 269: 14149-14152.
15. Emeis J J, Kooistra T. Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266.
16. Colucci M, Paramo J A.Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 814-824.
17. Suffredini A F, Harpel P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N EnglJMed 1989; 320: 1165-1172.
18. Quax P H A, van den Hoogen C M, Verheijen J H et al. Endotoxin induction of plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15560-15563.
19. Emeis J J, van den Hoogen C M. Pharmacological modulation of the endotoxin-induced increase in plasminogen activator inhibitor activity in rats. Blood Coagul Fibrinolysis 1992; 3: 575-581.
20. Colucci M, Paramo J A, Stassen J M, Collen D. Influence of the fast-acting inhibitor on in vivo thrombolysis induced by tissuetype plasminogen activator in rabbits. J Clin Invest 1986; 78: 138-144.
21. Pralong G, Calandra T, Glauser M-P et al. Plasminogen activator inhibitor l : A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462.
22. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
23. Almer L, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 1987; 47: 335-339.
24. Heikki Frick M, Flo O, Haapa K et al. Helsinki Heart Study: Primary-prevention trial with gemflbrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245.
25. Manninen V, Elo O, Heikki Frick M et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-651.
26. Manninen V, Huttunen J K, Heinonen O P, Tenkanen L, Heikki Frick M. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63: 42H-47H.
27. Heikki Frick M, Manninen V, Huttunen J K, Heinonen O P, Tenkanen L, Manttari M. HDL-cholesterol as a risk factor in coronary heart disease: An update of the Helsinki Heart Study, Drugs 1990; 40(Suppl 1): 7-12.
28. Canner P L, Berge K G, Wenger N K et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
29. Weiner M, Redisch W, Steel J M. Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc Soc Exp BiolMed 1958; 98: 755-757.
30. Weiner M, DeCrinis K, Redisch W, SteeleJ M. Influence of some vasoactive drugs on fibrinolytic activity. Circulation 1959; 19: 845-848.
31. Fujii S, Sobel B E. Direct effects of gemflbrozil on the fibrinolytic system: Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992; 85: 1888-1893.
32. Fujii S, Sawa H, Sobel B E. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost 1993; 70: 642-647.
33. Brown S L, Sobel B E, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995; 92: 767-772.